Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TALS
- Price
- -
- Stock movement down
- -27.40 (-99.99%)
- Company name
- Talaris Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 128.43K
- Ent value
- -58.77M
- Price/Sales
- -
- Price/Book
- 0.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -99.99%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
TALS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.00 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 42.81M |
| EPS (TTM) | -13.50 |
| FCF per share (TTM) | -12.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -69.34M |
| Net income (TTM) | -57.66M |
| EPS (TTM) | -13.50 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 67.08M |
| Net receivables | 0.00 |
| Total current assets | 151.05M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 151.06M |
| Accounts payable | 136.00K |
| Short/Current long term debt | 634.00K |
| Total current liabilities | 8.11M |
| Total liabilities | 8.19M |
| Shareholder's equity | 142.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -52.47M |
| Capital expenditures (TTM) | 810.00K |
| Free cash flow (TTM) | -53.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -40.35% |
| Return on Assets | -38.17% |
| Return on Invested Capital | -40.18% |
| Cash Return on Invested Capital | -37.12% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| TALS | S&P500 | |
| Current price drop from All-time high | -100.00% | -10.73% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 19 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -62.89% | -11.07% |
| Avg time to new high | 124 days | 12 days |
| Max time to new high | 598 days | 1805 days |
COMPANY DETAILS
Marketcap
128.43K
Marketcap category
Small-cap
Description
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc., in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
Employees
84
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner